In this article, we elaborate on the early involvement of health technology assessment in translational research and the concept of coverage with evidence development in The Netherlands Cancer Institute and give two case examples that are currently ongoing; (1) tumour infiltrating lymphocytes therapy for metastatic melanoma; and (2) high-dose chemotherapy for BRCA1-like subgroup in triple-negative breast cancer. Here, BRCA1 is linked to triple-negative breast carcinoma.